Analysis for ZTS

📈 Growth & Financial Trajectory

Across the five observed quarters (2025 Q1 to 2026 Q1), Zoetis' revenues rose from $2.22B to around $2.26B, with a peak near $2.40B in 2025 Q3 before a modest dip to $2.26B in 2026 Q1. Net income grew from $631M in Q1 2025 to a high around $721M in late 2025, then edged down to $601M in 2026 Q1. Overall revenue is up ~2% with earnings broadly flat, signaling stability with a mid-2025 strength normalization.

💰 Margins & Cash Flow

Gross profit margins hovered in the 72-77% range, and operating margins run in the 33-38% band, indicating robust profitability. Cash flow was generally positive from operating activities across quarters, with notable strength in late 2025, but 2026 Q1 shows a negative net cash flow driven by financing and investing outflows despite solid operating cash flow (~+$401M).

🛡️ Balance Sheet & Liquidity

Total assets sit near $14-15B, with equity around $4.9-5.0B and liabilities roughly $9-11B. This yields a comfortable balance sheet with ample liquidity and an equity cushion, supporting resilience through quarterly fluctuations. Current assets often exceed current liabilities, underscoring solid near-term liquidity.

⚠️ Key Drivers & Risks

• Drivers: Durable demand in the animal-health market (vaccines, parasiticides) and steady macro tailwinds in veterinary care.
• Risks: Moderate cyclicality in budgets and margin sensitivity to commodity/inputs or M&A-related costs; valuation could remain sensitive to earnings cadence.